From Nitrobenzenes to Substituted Tetrahydroquinolines in a Single Step by a Domino Reduction / Imine Formation / Aza-Diels–Alder Reaction

Hans-Georg Imrich,[†] Jürgen Conrad,[†] Denis Bubrin[‡] and Uwe Beifuss^{*,†}

[†]Bioorganische Chemie, Institut für Chemie, Universität Hohenheim, Garbenstraße 30, D-70599 Stuttgart, Germany

[‡]Institut für Anorganische Chemie, Universität Stuttgart, Pfaffenwaldring 55, D-70569

Stuttgart, Germany

ubeifuss@uni-hohenheim.de

Supporting Information

Table of contents

Figures 1-21	NMR spectra of compounds 5a-r, and 8	S2-S22
Figures 22-24	X-ray crystal structures of compounds 5b , 5d and 5h	S23-S25



Figure 1. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5a in CDCl₃.



(3aSR,4SR,9bRS)-4-Phenyl-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline (*exo*-5a)

Figure 2. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *exo*-5a in CDCl₃.



(3a*SR*,4*RS*,9b*RS*)-6-Bromo-4-phenyl-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline (*endo*-**5b**)

Figure 3. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5b in CDCl₃.



(3a*SR*,4*RS*,9b*RS*)-7-Bromo-4-phenyl-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline (*endo*-**5**c)

Figure 4. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5c in CDCl₃.





Figure 5. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5d in CDCl₃.



(3a*SR*,4*SR*,9b*RS*)-8-Bromo-4-phenyl-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline (*exo*-**5d**)

Figure 6. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *exo*-5d in CDCl₃.



(3a*SR*,4*RS*,9b*RS*)-4-Phenyl-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline-8-carbonitrile (*endo*-5e)

Figure 7. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5e in CDCl₃.



(3a*SR*,4*RS*,9b*RS*)-8-Methoxy-4-phenyl-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline (*endo*-**5f**)

Figure 8. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5f in CDCl₃.



(3a*SR*,4*RS*,9b*RS*)-8-Methyl-4-phenyl-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline (*endo*-**5**g)

Figure 9. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5g in CDCl₃.



(3a*SR*,4*RS*,9b*RS*)-4-(4-Fluorophenyl)-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline (*endo*-**5h**)

Figure 10. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5h in CDCl₃.



(3a*SR*,4*RS*,9b*RS*)-4-(4-Chlorophenyl)-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline (*endo*-**5**i)

Figure 11. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5i in CDCl₃.



(3a*SR*,4*RS*,9b*RS*)-4-(4-Bromophenyl)-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline (*endo*-**5j**)

Figure 12. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5j in CDCl₃.



4-((3a*SR*,4*RS*,9b*RS*)-3a,4,5,9b-Tetrahydro-3*H*-cyclopenta[*c*]quinolin-4-yl)benzonitrile (*endo*-**5**k)

Figure 13. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5k in CDCl₃.





Figure 14. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5l in CDCl₃.



(3a*SR*,4*RS*,9b*RS*)-4-(Methoxyphenyl)-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline (*endo*-**5m**)

Figure 15. ¹H (300 MHz) and ¹³C (75 MHz) NMR spectra of *endo*-5m in CDCl₃.



(3a*SR*,4*RS*,9b*RS*)-4-p-Tolyl-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline (*endo*-**5n**)

Figure 16. ¹H (300 MHz) and ¹³C (75 MHz) NMR spectra of *endo*-5n in CDCl₃.





Figure 17. ¹H (300 MHz) and ¹³C (75 MHz) NMR spectra of *endo*-50 in CDCl₃.





Figure 18. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5p in CDCl₃.



(3aSR,4RS,9bRS)-4-Cyclohexyl-3a,4,5,9b-tetrahydro-3*H*-cyclopenta[*c*]quinoline (*endo*-5q)

Figure 19. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5q in CDCl₃.





Figure 20. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of *endo*-5r in CDCl₃.



Figure 21. 1 H (500 MHz) and 13 C (125 MHz) NMR spectra of 8 in CDCl₃.





Figure 22. X-ray crystal structure of (3a*SR*,4*RS*,9b*RS*)-6-bromo-4-phenyl-3a,4,5,9b-tetrahydro-*3H*-cyclopenta[*c*]quinoline (**5b**)



Figure 23. X-ray crystal structure of (3a*SR*,4*RS*,9b*RS*)-8-bromo-4-phenyl-3a,4,5,9b-tetrahydro-*3H*-cyclopenta[*c*]quinoline (**5d**)



9 H, Jaa 3 9 9 H, Jaa 3 9 9 9 4 6 5 a N 5 1 6 H 5 1 6 5 4 F

Figure 24. X-ray crystal structure of (3*aSR*,4*RS*,9*bRS*)-4-(4-fluorophenyl)-3*a*,4,5,9*b*-tetrahydro-*3H*-cyclopenta[*c*]quinoline (**5h**)